One amyloid candidate left for Biogen, Eisai after axing BACE trials

Despite ending two Phase III trials of BACE inhibitor elenbecestat Friday, Biogen and Eisai have not walked away from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401 forges on, treating about 1,600 more patients with an amyloid agent.

Biogen Inc. (NASDAQ:BIIB) and Eisai

Read the full 504 word article

User Sign In